[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-hematologic-malignancies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-hematologic-malignancies":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643202","canut-junior--assessment-of-sensory-abilities-and-eating-behavior-in-pediatric-oncology-a-feasibility-study-100643202",false,"NCT07632560","CANUT Junior : Assessment of Sensory Abilities and Eating Behavior in Pediatric Oncology: a Feasibility Study","CANUT Junior","Inclusion Criteria:\n\n* Patients treated at a pediatric oncology-hematology center, with an initial diagnosis of a solid or hematological tumor, aged 7 to 17 years inclusive.\n* Patients with functional oral feeding\n* Parent\u002Fguardian who has signed the informed consent form and patient who has not expressed refusal\n* Patients affiliated with the social security system\n* French-speaking patients\n* Validated indication for systematic oncological treatment\n\nExclusion Criteria:\n\n* Individuals with a known food allergy\u002Fintolerance to the prototypes being studied (does not apply to patients on a protected diet)\n* Individuals who have undergone surgery on the tongue\n* Patients for whom other types of cancer treatment are planned during the study period (e.g., radiation therapy)\n* Patients with dental conditions\n* Patients who have relapsed","ALL","7 Years","17 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer treatments in children are very intense and often cause side effects such as nausea, vomiting, loss of appetite, and changes in taste and smell. These sensory alterations can impact eating habits, but they are still poorly understood in children. The study aims to assess whether it is feasible to measure these sensory changes (taste, smell, salivation, and food preferences) in children and adolescents undergoing cancer treatment.\n\nThis study is a feasibility study with 30 patients aged 7 to 17 years, treated at the Pediatric Hematology and Oncology Institute (IHOPE) in Lyon. Sensory tests and questionnaires to evaluate the perceptions, oral health, eating habits, nutritional status, and quality of life are used.\n\nThe inclusion was initially planned at diagnosis, before any administration of chemotherapy. However, the study quickly encountered a recruitment problem due to the emotional impact and medical burden of this initial period of care (study offered to 11 families over a period of 5 months, 3 patients included). An amendment to the protocol was therefore made to be able to modify the inclusion period after the completion of chemotherapy. This modification was implemented on May 15, 2025, and allowed the inclusion of two new patients, making a total of 5 patients. Of these 5 patients, two completed all the tests during V0 and V1, two completed V0 but not V1, one did not complete any of the visits.\n\nThis feasibility phase will help determine whether the tools are suitable and well accepted. The results will be used to design a larger study aimed at better understanding how taste and smell alterations influence the eating behaviors of young patients during cancer treatment. Recruitment will continue for six more months in order to reach the target number of participants.",[27,28],"Pediatric Hematologic Malignancies","Pediatric Oncology",[30,31,32,33],"taste alteration","sensory alteration","chemotherapy","pediatrics","RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2024-12-13",{"date":42,"type":21},"2026-06",{"name":44,"class":45},"Centre Leon Berard","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100440140","phase-1-haploidentical-hematopoietic-stem-cell-transplantation-with-ex-vivo-tcr-alphabeta-and-cd19-depletion-in-pediatric-hematologic-malignancies-100440140","NCT05011422","Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha\u002FBeta and CD19 Depletion in Pediatric Hematologic Malignancies","A Pilot Study of Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha\u002FBeta and CD19 Depletion in Pediatric Hematologic Malignancies","Recipient Inclusion Criteria:\n\n* Must meet at least one of the following disease criteria:\n\n  * B cell ALL in first remission and any of the following:\n\n    * Persistent flow-based MRD at end-of-consolidation:\n\n      * ≥ 1% for NCI SR ALL\n      * ≥ 0.01% for NCI HR ALL\n    * TCF3-HLF t(17;19)\n    * KMT2A rearranged infant ALL, \\\u003C 6 months of age and presenting WBC of \\> 300,000 or poor steroid response (peripheral blasts \\>= 1000 \u002FuL on day 8 of therapy\n    * Other high-risk features not explicitly stated here, after discussion\u002Fapproval with protocol PI.\n  * B cell ALL in second remission and any of the following:\n\n    * Early (\\\u003C36 months from start of therapy) marrow or combined relapse\n    * Late (\\>36 months from start of therapy) marrow or combined relapse with end-of re-induction flow MRD \\>= 0.1%\n    * Early isolated extramedullary relapse (\\\u003C 18 months from start of therapy)\n  * Any B cell ALL in third or greater remission\n  * T cell ALL in first remission\n\n    * End-of consolidation MRD \\> 0.1%\n  * Any T cell ALL in second or greater remission\n  * AML in first remission with any of the following high-risk features:\n\n    * MRD ≥ 1% after first induction course\n    * MRD ≥ 0.1% after second induction course\n    * RPN1-MECOM\n    * RUNX1-MECOM\n    * NPM1-MLF1\n    * DEK-NUP214\n    * KAT6A-CREBBP (if \\>= 90 days at diagnosis)\n    * FUS-ERG\n    * KMT2A-AFF1\n    * KMT2A-AFDN\n    * KMT2A-ABI1\n    * KMT2A-MLLT1\n    * 11p15 rearrangement (NUP98 - any partner gene)\n    * 12p13.2 rearrangement (ETV6 - any partner gene)\n    * Deletion 12p to include 12p13.2 (loss of ETV6)\n    * Monosomy 5\u002FDel(5q) to include 5q31 (loss of EGR1)\n    * Monosomy 7\n    * 10p12.3 rearrangement (MLLT10b - any partner gene)\n    * FLT3\u002FITD with allelic ratio \\> 0.1%\n    * RAM phenotype as evidenced by flow cytometry: bright CD56+, dim to negative CD45 and CD38 and lack of HLA-DR\n    * Other high-risk features not explicitly stated here, after discussion\u002Fapproval with protocol PI.\n  * AML in second or greater remission\n  * Mixed phenotype or undifferentiated leukemia in any CR\n  * Secondary to therapy-associated leukemia in any CR\n  * NK cell lineage leukemia in any CR\n  * Myelodysplastic syndrome (MDS)\n  * Juvenile myelomonocytic leukemia (JMML)\n* May have undergone a prior hematopoietic stem cell transplant provided one of the criteria in Inclusion Criterion #1 are met AND the patient does not have active GVHD (has been off immunosuppression for at least 3 months).\n* Available familial haploidentical donor.\n* Donor and recipient must be identical at a minimum of one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. A minimum of 5\u002F10 match is required and will be considered sufficient evidence that the donor and recipient share one HLA haplotype.\n* No more than 30 years of age\n* Lansky or Karnofsky performance status \\> 50%\n* Adequate organ function as defined below:\n\n  * Cardiac: LVEF ≥ 40% at rest or SF ≥ 26%\n  * Hepatic:\n\n    * Total bilirubin \\\u003C 3 x IULN for age\n    * AST(SGOT)\u002FALT(SGPT) \\\u003C 5 x IULN\n  * Renal: GFR ≥ 60 mL\u002Fmin\u002F1.73m2 as estimated by updated Schwartz formula for ages 1-17 years (see Appendix B), 24-hour creatinine clearance, or renal scintigraphy. If GFR is abnormal for age based on updated Schwartz formula, accurate measurement should be obtained by either 24-hour creatinine clearance or renal scintigraphy. Renal function may also be estimated by serum creatinine based on age\u002Fgender. A minimum serum creatinine of 2x upper limit of normal is required for inclusion on this protocol.\n  * Pulmonary:\n\n    * O2 saturation ≥ 92% on room air without positive pressure support\n    * FEV1, FVC, and DLCO ≥ 50% of predicted (for children unable to perform a pulmonary function test, a high-resolution CT chest may be obtained)\n* The effects of these treatments on the developing human fetus are unknown. For this reason, patients of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for 24 months following transplant. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nRecipient Exclusion Criteria:\n\n* Available matched related donor. A patient with a matched unrelated donor is eligible if urgent transplantation is required. A prior unrelated donor search is not required for enrollment.\n* Active non-hematologic malignancy. History of other malignancy is acceptable as long as therapy has been complete and there is no evidence of disease.\n* Currently receiving any other investigational agents at the time of transplant.\n* Active CNS or extramedullary disease. History of CNS or extramedullary disease now in remission is acceptable.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to conditioning agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (bacterial, viral with clinical instability, or fungal), symptomatic congestive heart failure, or unstable cardiac arrhythmia.\n* Presence of significant anti-donor HLA antibodies per institutional standards. Anti-donor HLA Antibody Testing is defined as a positive crossmatch test of any titer (by complement dependent cytotoxicity or flow cytometric testing) or the mean fluorescence intensity (MFI) of any anti-donor HLA antibody by solid phase immunoassay.\n* Presence of a second major disorder deemed a contraindication for HSCT.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of the start of conditioning.\n\nDonor Eligibility Criteria:\n\n* At least 6 months of age\n* Meets the selection criteria as defined by the Foundation for the Accreditation of Hematopoietic Cell Therapy (FACT).\n* Able to understand and willing to sign an IRB-approved written informed consent document (or that of legally authorized representative, if applicable).","30 Years",{"count":56,"type":21},50,[58],"PHASE1","This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft modification technique (selective αβ-TCR and CD19 depletion).",[27],"2026-03-13",{"date":63,"type":38},"2026-03-16",{"date":65,"type":38},"2022-11-03",{"date":67,"type":21},"2029-05-31",{"name":69,"class":45},"Washington University School of Medicine"]